Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation

Yasmin A Lyons; Michael Frumovitz; Pamela T Soliman

doi:10.1016/j.gore.2014.09.003

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation

Gynecol Oncol Rep. 2014 Oct 25:10:28-9. doi: 10.1016/j.gore.2014.09.003. eCollection 2014 Dec.

Authors

Yasmin A Lyons¹, Michael Frumovitz², Pamela T Soliman²

Affiliations

¹ Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, United States.
² Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Abstract

•Molecular testing may play a role in the determination of targeted therapy treatment options.•Targeted therapy provides treatment options for recurrent cervical cancer.•MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.

Keywords: KRAS mutation; MEK inhibitor; Small cell neuroendocrine carcinoma.